计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 ,适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Tucatinib (Irbinitinib, ONT-380, ARRY-380) 是一种具有口服活性、可逆的、ATP竞争性的的ErbB2(HER2)小分子抑制剂。在细胞实验中,ARRY-380对ErbB-2和p95 HER2的IC50s分别为8 nM和7 nM,对HER2的选择性是对EGFR的500倍。具有潜在的抗肿瘤活性。
Information
Tucatinib (Irbinitinib, ONT-380, ARRY-380) is an oral, potent, selective, reversible and ATP-competitive small-molecule inhibitor ofErbB-2(also called HER2) with IC50s of 8 nM and 7 nM for ErbB-2 and p95 HER2, respectively in cell-based assays, showing ~5
In vitro
The compound is a reversible, ATP-competitive inhibitor with nanomolar potency against ErbB2 in both in vitro and in cell-based assays. Incell-based assays, ARRY-380 is ~500-fold selective for HER2 vs. EGFR and is equipotent against truncated p95-HER2.
In vivo
In vivo, ARRY-380 significantly inhibits tumor growth in multiple HER2-dependent tumor xenograft models. It shows excellent activity in numerous mouse tumor models including breast (BT-474, MDA-MB-453), ovarian (SKOV-3) and gastric (N87) carcinoma models. In the BT-474 model, ARRY-380 demonstrated significant dose-related tumor growth inhibition (TGI; 50% at 50 mg/kg/d and 96% at 100 mg/kg/d) with numerous partial regressions (>50% reduction from baseline size).
Cell Data
cell lines:Human vascular endothelial cells (HUVECs)
Concentrations:
Incubation Time:
Powder Purity:≥97%
| IC50 | ErbB2, IC50: 8 nM |
|---|---|
| ALogP | 4.744 |
| HBD Count | 2 |
| Rotatable Bond | 6 |
H302: 吞食有害
H361: 怀疑破坏生育力或未出生的孩子
H371: 可能会损坏器官
H373: 通过长时间或反复暴露对器官造成损害